ROIVRoivant Sciences Ltd.
$36.49+113% 1Y
$36.49
$17.2652 weeks$41.81
ROIV in its own filings
Nothing in ROIV's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
164
Events found in the filings · across 988 filings · the record starts in 2015
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 21, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 16, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2023-09-01
- SEC comment-letter activity17 occurrences
- 2023-10-04
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 21, 2026Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)Regulation FD disclosure · press release
- Sep 8, 2026Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with.Regulation FD disclosure · press release
- Aug 28, 2026On August 28, 2026, Roivant Sciences Ltd. (the “Company”) posted a presentation regarding the approval by the U.S. Food and Drug Administration of LISRAYA™ (brepocitinib) for the treatment of adults with dermatomyositis on the “Events & Presentations” page of its investor relations website at investor.roivant.com.Other event · Form 8-K
- Aug 27, 2026Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.Regulation FD disclosure · press release
- Apr 2, 2026Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study.Earnings release · press release
- Mar 23, 2026The disclosure set forth in.Material agreement entered · Form 8-K/A
- Mar 3, 2026On March 3, 2026 (the “Effective Date”), Genevant Sciences GmbH (“Genevant”), a subsidiary of Roivant Sciences Ltd. (the “Company” or “Roivant”), Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. …Material agreement entered · Form 8-K
- Mar 3, 2026Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…